From The Motley Fool · The Motley Fool Team · · 50s
Tempus AI: 3 Key Takeaways for Long-Term Investors
Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors.
In brief
Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors. Tempus AI's third-quarter 2026 earnings report $411.5M revenue up 23% YoY with $193M data licensing and $80M oncology ASP gains expected by 2027. Originally reported by The Motley Fool.
Q3 2026 Revenue
Tempus AI reported third-quarter 2026 revenue of $411.5 million, up 23% year over year.
Multiyear Biopharma Deals
Long-term licensing agreements with biopharma partners like Pathos AI generate $193 million in data revenue over five years.
“Through this collaboration, Pathos is paying Tempus $55 million over a 5-year term. As a result, over the next approximately 5 years, we expect to generate $193 million of additional data and applications revenue from these agreements alone.”
Oncology Pricing Boost
FDA-approved pricing changes will add $80 million in oncology average selling price gains by 2027.
“Given the expansion of our FDA approval to include tumor-only for XT test, that updated pricing will kick in on January 1 and allow us to move the remaining XT over. That gives us about $80 million of uplift in oncology ASP in 2027.”
Positive Adjusted EBITDA
Tempus achieved positive adjusted EBITDA of $25.6 million in Q3 2026 after gross profit growth outpaced investments.
The bottom line
Tempus AI's third-quarter 2026 earnings report $411.5M revenue up 23% YoY with $193M data licensing and $80M oncology ASP gains expected by 2027.
Read the TL;DR — this story on one card.

